Literature DB >> 19704054

Phase I drug combination trial design: walking the tightrope.

Paul Hamberg, Jaap Verweij.   

Abstract

Mesh：

Year:  2009        PMID： 19704054     DOI： 10.1200/JCO.2009.23.6703

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  10 in total

Review 1.  Moving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial design.

Authors:  Jaap Verweij; Maja de Jonge; Ferry Eskens; Stefan Sleijfer
Journal:  Mol Oncol       Date:  2012-02-16       Impact factor: 6.603

Review 2.  Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents.

Authors:  Christophe Le Tourneau; Véronique Diéras; Patricia Tresca; Wulfran Cacheux; Xavier Paoletti
Journal:  Target Oncol       Date:  2010-04-02       Impact factor: 4.493

3.  A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies.

Authors:  John F Deeken; Hongkun Wang; Deepa Subramaniam; Aiwu Ruth He; Jimmy Hwang; John L Marshall; Christina E Urso; Yiru Wang; Corinne Ramos; Kenneth Steadman; Michael J Pishvaian
Journal:  Cancer       Date:  2015-01-29       Impact factor: 6.860

4.  Dosing Three-Drug Combinations That Include Targeted Anti-Cancer Agents: Analysis of 37,763 Patients.

Authors:  Mina Nikanjam; Sariah Liu; Jincheng Yang; Razelle Kurzrock
Journal:  Oncologist       Date:  2017-04-19

Review 5.  Determining the optimal dose in the development of anticancer agents.

Authors:  Ron H J Mathijssen; Alex Sparreboom; Jaap Verweij
Journal:  Nat Rev Clin Oncol       Date:  2014-03-25       Impact factor: 66.675

6.  Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns.

Authors:  Mina Nikanjam; Harsh Patel; Razelle Kurzrock
Journal:  Oncoimmunology       Date:  2017-06-28       Impact factor: 8.110

Review 7.  Analysis of the yield of phase II combination therapy trials in medical oncology.

Authors:  Michael L Maitland; Christine Hudoba; Kelly L Snider; Mark J Ratain
Journal:  Clin Cancer Res       Date:  2010-09-13       Impact factor: 12.531

8.  Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide.

Authors:  Peter H O'Donnell; Sanja Karovic; Theodore G Karrison; Linda Janisch; Matthew R Levine; Pamela J Harris; Blase N Polite; Ezra E W Cohen; Gini F Fleming; Mark J Ratain; Michael L Maitland
Journal:  Clin Cancer Res       Date:  2015-07-21       Impact factor: 12.531

Review 9.  Adaptive designs for dual-agent phase I dose-escalation studies.

Authors:  Jennifer A Harrington; Graham M Wheeler; Michael J Sweeting; Adrian P Mander; Duncan I Jodrell
Journal:  Nat Rev Clin Oncol       Date:  2013-03-19       Impact factor: 66.675

10.  Dosing targeted and cytotoxic two-drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013.

Authors:  Mina Nikanjam; Sariah Liu; Razelle Kurzrock
Journal:  Int J Cancer       Date:  2016-07-22       Impact factor: 7.396
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.